CASTLE BIOSCIENCES, INC. Debt Securities, Available-for-sale, Amortized Cost
CASTLE BIOSCIENCES, INC. (CSTL) had Debt Securities, Available-for-sale, Amortized Cost of $169.64 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-02-27
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost $169.64M.
- 2024-09-30: Debt Securities, Available-for-sale, Amortized Cost $184.35M.
- 2024-06-30: Debt Securities, Available-for-sale, Amortized Cost $174.29M.
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost $156.37M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2024-12-31 | $169.64M 10-K · filed 2025-02-27 |
| 2024-09-30 | $184.35M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $174.29M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $156.37M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $144.12M 10-K · filed 2025-02-27 |
| 2023-09-30 | $138.60M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $129.78M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $117.37M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $136.06M 10-K · filed 2024-02-28 |
| 2022-09-30 | $131.99M 10-Q · filed 2022-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |